Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Imugene Receives Ethics Approval to Start Phase 2 NextHERIZON Clinical Trial of Cancer Immunotherapy HER-Vaxx

10 May 2022  |  08:42:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON

Imugene announced that it has received Human Research Ethics Committee (HREC) approval to commence a Phase 2 clinical trial of its immunotherapy candidate, HER-Vaxx in Australia. Ethics approval is confirmation that it has completed all the necessary pre-clinical safety and efficacy testing of HER-Vaxx required to commence its nextHERIZON clinical trial in Australia. The Australian component of the Phase 2 trial will be conducted under Australia's Clinical Trials Notification (CTN) Scheme meaning Imugene will notify the Therapeutic Goods Administration (TGA) of HREC approval and complete local site initiation activities. The first hospital to receive ethics approval is the Queen Elizabeth Hospital, Adelaide Australia under the direction of Principal Investigator Dr Tim Price.

Please click here for full details

See more ASX300 News Announcements